Table 3.
Percent of patients with LPC concentrations below the limit of quantification (LoQ), median individual apparent LPV clearance and LPV exposure (AUC0-12) versus virologic treatment outcomes at week 12 and 48.
| Patients with concentrations below LoQ (%) | p -value* | CL/F (L/h) (median [IQR]) | p-value* | AUC0-12 (h∙mg/L) (median [IQR]) | p-value* | |
|---|---|---|---|---|---|---|
| Treatment outcome week 12 (n= 54), LTFU=4, Missing VL=4 | ||||||
| Failure (n=38) | 28% | 0.41 | 4.5 [1.9 – 11.9] | 0.79 | 23.6 [10.2 – 62.8] | 0.98 |
| Success (n=16) | 42% | 4.3 [2.1 – 12.6] | 28.4 [ 9.0 – 61.8] | |||
| Treatment outcome week 48 (n=58), LTFU =8, Missing VL=4 | ||||||
| Failure (n=17) | 41% | 0.44 | 3.8 [1.7 – 13.9] | 0.95 | 25.5 [ 8.7 – 69.0] | 0.90 |
| Success (n=33) | 30% | 3.5 [2.0 – 10.4] | 31.4 [11.8 – 60.8] | |||
*
compared to ‘Failure’ category, n - number of patients included, LoQ - Limit of Quantification, LPV – lopinavir, CL/F – apparent LPV clearance (l/h)